

NOVAVAX INC  
Form 8-K  
July 21, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO 13 or 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): July 19, 2004

**NOVAVAX, INC.**

(Exact name of registrant as specified in its charter)

<b><u>Delaware</u></b> (State or other jurisdiction of incorporation or organization)	<b><u>0-26770</u></b> (Commission File No.)	<b><u>22-2816046</u></b> (I.R.S. Employer Identification No.)
---	---	---

<b><u>8320 Guilford Road, Columbia,</u></b> <b><u>MD</u></b> (Address of principal executive offices)	<b><u>21046</u></b> (Zip code)
--	-----------------------------------

**(301) 854-3900**  
Registrant's telephone number, including area code

**Not applicable**  
(Former name or former address, if changed since last report)

**NOVAVAX, INC.**  
**ITEMS TO BE INCLUDED IN THIS REPORT**

**ITEM 5. OTHER EVENTS.**

On July 19, 2004, Novavax, Inc. closed its previously announced \$40 million in financings and its transaction with King Pharmaceuticals, Inc.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVAVAX, INC.

Date: July 20, 2004

By: /s/ Dennis W. Genge  
Dennis W. Genge  
Vice President and Chief Financial  
Officer